ACUMEN PHARMACEUTICALS INC ANTICIPATES TOPLINE RESULTS FOR ALTITUDE-AD PHASE 2 STUDY BY LATE 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 4 days ago

0mins

ABOS-3.1%

Should l Buy ABOS?

Source: moomoo

Company Overview: Acumen Pharmaceuticals is focused on developing treatments for Alzheimer's disease, particularly through its innovative drug candidates.
Study Expectations: The company anticipates releasing results from its Phase 2 study of the drug candidate, known as ACU193, in late 2026, which aims to assess its efficacy in treating Alzheimer's.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ABOS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ABOS

Wall Street analysts forecast ABOS stock price to rise

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.260

Low

4.00

Averages

7.00

High

10.00

Current: 2.260

Low

4.00

Averages

7.00

High

10.00

BTIG

Buy

maintain

$7 -> $8

2026-03-17

Reason

BTIG

Price Target

$7 -> $8

AI Analysis

2026-03-17

maintain

Buy

Reason

BTIG raised the firm's price target on Acumen to $8 from $7 and keeps a Buy rating on the shares. Recent updates suggest multiple TfR-binding scaffolds may meaningfully enhance central nervous system delivery without causing anemia, the analyst tells investors in a research note. Its next candidate, building on lessons from IZCARGO, appears designed to retain Sabirnetug's high selectivity for toxic A-beta oligomers over plaque and monomers, potentially enabling strong efficacy with reduced ARIA risk and a best-in-class safety profile, the firm says.

BTIG

NULL -> Buy

upgrade

$4 -> $7

2026-01-27

Reason

BTIG

Price Target

$4 -> $7

2026-01-27

upgrade

NULL -> Buy

Reason

BTIG raised the firm's price target on Acumen to $7 from $4 and keeps a Buy rating on the shares. The rollout of Biogen's (BIIB) two commercial drugs LEQEMBI and KISUNLA has been slow, partially due to the infusions required to deliver these drugs, but the news that the FDA has accepted sBLA for LEQEMBI SubQ induction therapy with priority review status is a "nice positive for the future of the field" in Alzheimer's disease treatment, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABOS

Unlock Now

About ABOS

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Acumen Pharmaceuticals Files to Sell 10.83M Shares of Common Stock

3 days agoseekingalpha

Stock Offering Plan: Acumen Pharmaceuticals has filed to sell 10.83 million shares of common stock, although this prospectus does not constitute an offer to sell, which may impact the ownership stakes of existing shareholders.
Clinical Trial Progress: Acumen aims to report results from its ALTITUDE-AD Phase II clinical trial by late 2026, and if successful, this could provide significant support for the company's competitive position in the Alzheimer's market.
Funding Support: The company is advancing its EBD program with $36 million in funding, which will help accelerate its research and development efforts and enhance the market potential of its product pipeline.
Financial Transparency: Acumen Pharmaceuticals has provided historical financial data to improve investor understanding of its financial condition, thereby enhancing market confidence and attracting potential investors.

Acumen Pharmaceuticals Q4 2025 Earnings Call Insights

3 days agoseekingalpha

Significant R&D Progress: Acumen Pharmaceuticals reported in Q4 2025 that sabirnetug showed promising results in the ALTITUDE-AD trial, emphasizing its high selectivity for A-beta oligomers, which could lead to improved clinical efficacy and safety, highlighting the company's potential in Alzheimer's treatment.
Enhanced Funding Support: The company successfully completed a $35.75 million private placement in March 2026 to support the Enhanced Brain Delivery (EBD) program, which is expected to provide financial backing for future clinical candidates, helping Acumen maintain its competitive edge in the biopharmaceutical market.
Strong Financial Position: As of the end of 2025, Acumen reported $116.9 million in cash and marketable securities, sufficient to support its operations and R&D activities into early 2027, despite a net loss of $121.3 million in 2025, reflecting the company's ongoing commitment to R&D investment.
Positive Future Outlook: Management anticipates key clinical data from ALTITUDE-AD to be released by the end of 2026, which will inform the company's future strategic direction, while also laying the groundwork for an IND filing for the EBD program, indicating Acumen's long-term growth potential in Alzheimer's treatment.

Acumen Pharmaceuticals FY 2025 Earnings Beat Expectations

4 days agoseekingalpha

Earnings Surprise: Acumen Pharmaceuticals reported a FY 2025 GAAP EPS of -$2.00, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in the red.
Strong Cash Reserves: As of December 31, 2025, Acumen's cash, cash equivalents, and marketable securities totaled $116.9 million, which is expected to support the company's current clinical and operational activities into early 2027, ensuring short-term operational stability.
Ongoing Clinical Activities: The company's sufficient funding over the next two years will enable it to continue advancing clinical trials and other critical operational activities, demonstrating Acumen's ongoing commitment to R&D, which may lay the groundwork for future product launches.
Increased Market Attention: Following the earnings release, Acumen Pharmaceuticals has garnered heightened market attention, with investors showing greater interest in its future clinical progress and financial health, which could influence its stock price trajectory.